On 17 June 2026 the Official Journal of the EU published two Commission Implementing Decisions extending the harmonised standards lists for medical devices and in vitro diagnostics. Both entered into force on the day of publication.
Implementing Decision (EU) 2026/1231 (11 June 2026) does two things. First, it replaces five existing entries with their 2025 amendments: EN ISO 10993-23, -12 and -17 (biological evaluation), EN IEC 60601-2-83 (home light therapy equipment) and EN ISO 15223-1 (symbols). Second, it adds 14 new references, covering transfusion sets (EN ISO 1135-4/-5:2025), biological evaluation (EN ISO 10993-1:2025; EN ISO 10993-5:2009/A11:2025), ophthalmic optics (EN ISO 14889:2025), mammary implants (EN ISO 14607:2025), washer-disinfectors (EN ISO 15883-1/-2/-3/-7:2025), prosthetics (EN ISO 22675:2025), sharps injury protection (EN ISO 23908:2025), and EN 60601-1:2006/A13:2024.
Implementing Decision (EU) 2026/1313 (15 June 2026) makes the equivalent single change under IVDR, adding EN ISO 15223-1:2021/A1:2025 to Decision (EU) 2021/1195.
As stated in numerous previous posts and announcements, the authorised representative symbol is changing under this regime for both medical devices regulations (MDR and IVDR). Amendment EN ISO 15223-1:2021/A1:2025 replaces the outdated “EC REP” (European Community) with “EU REP,” aligning the symbol with today’s European Union.
The change is purely editorial: no impact on device safety, performance, or the role and obligations of the authorised representative, and no prior notified body approval is needed for the labelling update.
A 5-year transition period runs until 17 June 2031, during which both “EC REP” and “EU REP” may be used. From that date, only “EU REP” applies; devices already on the market with “EC REP” may remain available.
The Commission published a separate guidance document, MDCG 2021-5 rev. 1-Appendix in this context.
Source: European Commission





